[HTML][HTML] Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

WP Yong, BC Goh, RA Soo, HC Toh, K Ethirajulu… - Annals of oncology, 2011 - Elsevier
WP Yong, BC Goh, RA Soo, HC Toh, K Ethirajulu, J Wood, V Novotny-Diermayr, SC Lee…
Annals of oncology, 2011Elsevier
Background The objective of this study was to assess the safety, maximum tolerated dose
(MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of SB939, a novel
histone deacetylase (HDAC) inhibitor, in patients with advanced solid malignancies.
Patients and methods Dose-escalating cohorts of three to six patients received SB939 orally
thrice weekly for 3 weeks in a 4-week cycle. Acetylated histone H3 (acH3) was measured in
peripheral blood mononuclear cells (PBMCs). Results Thirty patients treated at one of five …
Background
The objective of this study was to assess the safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of SB939, a novel histone deacetylase (HDAC) inhibitor, in patients with advanced solid malignancies.
Patients and methods
Dose-escalating cohorts of three to six patients received SB939 orally thrice weekly for 3 weeks in a 4-week cycle. Acetylated histone H3 (acH3) was measured in peripheral blood mononuclear cells (PBMCs).
Results
Thirty patients treated at one of five doses (10–80 mg/day) received 79 cycles of SB939 (range, 1–12 cycles). Dose-limiting toxic effects were fatigue, hypokalemia, troponin T elevation, and QTc prolongation. Peak plasma concentration (Cmax) and area under the concentration–time curve extrapolated to infinity increased dose proportionally. The MTD of SB939 was 80 mg/day. The mean elimination half-life and oral clearance of SB939 were 7.2 ± 0.6 h and 53.0 ± 8.5 l/h, respectively, with no substantial accumulation on day 15. An increase in acH3 was observed at hour 3 and correlated with dose and Cmax. Stable disease was seen in several tumor types treated at ≥40 mg. HDAC inhibition was consistently observed at 60 mg, the recommended dose.
Conclusions
SB939 can be safely administered at the recommended dose and reaches plasma levels that strongly inhibit HDAC in PBMCs. These data support further efficacy studies of SB939.
Elsevier